Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise

MT Newswires Live

Aug 29

Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.

Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.

Analysts at Visible Alpha forecasted a loss of 1.01 yuan.

Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.

Analysts at Visible Alpha estimated 545.9 million yuan in revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2563962970"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563962970\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563962970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563962970","market":"fut","top_or_hot":-1,"title":"Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise","media":"MT Newswires Live","content":"<html><body><p> Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.</p><p>Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.</p><p>Analysts at Visible Alpha forecasted a loss of 1.01 yuan.</p><p>Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.</p><p>Analysts at Visible Alpha estimated 545.9 million yuan in revenue.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEverest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-29 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.</p><p>Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.</p><p>Analysts at Visible Alpha forecasted a loss of 1.01 yuan.</p><p>Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.</p><p>Analysts at Visible Alpha estimated 545.9 million yuan in revenue.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2563962970","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563962970","pubTimestamp":1756431367,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Everest Medicines  reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.Analysts at Visible Alpha forecasted a loss of 1.01 yuan.Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.Analysts at Visible Alpha estimated 545.9 million yuan in revenue.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀","MDCO":"麦迪逊医药"},"translate_title":"Everest Medicines上半年亏损收窄，收入大幅增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":0.9,"MDCO":1},"content_text":"Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.Analysts at Visible Alpha forecasted a loss of 1.01 yuan.Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.Analysts at Visible Alpha estimated 545.9 million yuan in revenue.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}